The search that brings you here is usually one of two things: "veozah for hot flashes" or "veozah liver damage." Sometimes both, in that order. You heard about the new pill that treats hot flashes without hormones, you got excited, and then you met the black box warning and the blood-test schedule and the phrase "rare but serious liver injury," and now you're here at 11 PM wondering if this is a miracle or a trap.
It's neither. It's a real drug class with real evidence, a real monitoring schedule, and a very specific set of instructions that the internet has turned into a horror story because nobody explained it in plain language. That's this article's whole job.
First, what these pills actually are
Veozah (fezolinetant) and Lynkuet (elinzanetant) belong to the same drug class: neurokinin-3 receptor antagonists. Without getting deep into the pharmacology, here's the practical version: they work on the brain's temperature-regulation pathway rather than replacing hormones. That's the entire point of their existence - an option for women who can't take HRT (breast cancer history, blood clots, personal choice) and for whom "just suffer through it" was the old answer.
- Veozah (fezolinetant) - FDA-approved May 2023 for moderate to severe hot flashes due to menopause. Non-hormonal, taken as a pill Established: FDA.
- Lynkuet (elinzanetant) - FDA-approved October 24, 2025, also for moderate to severe hot flashes. Two 60 mg capsules at bedtime (one capsule for people on certain interacting medicines). Approved on the OASIS-1/2/3 trials, 1,423 participants, all women Established: FDA.
They are siblings, not rivals. Same class, same job, one year and a half apart.
The part everyone searches: the liver warning
On December 16, 2024, the FDA added a Boxed Warning - its most prominent warning - to Veozah's label for "rare but serious liver injury." The trigger was one postmarketing case: a patient with normal liver labs who, within about 40 days of starting the drug, developed significantly elevated liver enzymes and bilirubin along with symptoms - fatigue, nausea, itching, jaundice, pale stools, dark urine. When she stopped the medicine, her symptoms gradually went away and her labs slowly returned to normal Established: FDA.
Read that again, because the internet skips it: the case resolved when the drug was stopped. The FDA did not pull the drug. It did something more useful - it built a monitoring system around the risk.
The blood-test schedule, plainly
This is the "fine print" that actually matters, and it is blessedly specific:
- Before you start: hepatic blood tests - ALT, AST, ALP, and bilirubin (total and direct). No start if any of those is already twice the upper limit of normal.
- Every month for the first three months.
- Then at months 6 and 9.
And the stop rules, straight from the label: stop if liver transaminases exceed five times the upper limit of normal, or if they exceed three times the upper limit and bilirubin is more than twice the upper limit Established: FDA.
That's it. That's the schedule. It's not vague, it's not "your doctor will figure it out," it's a named list of tests on a named timeline. The anxiety is the unknown; the schedule is the known. If a clinician prescribes Veozah without this schedule, that's a conversation worth having.
The stop-on-symptom list (screenshot this)
Per the FDA, stop the pill immediately and call your prescriber if you get any of these:
- Unusual tiredness (more than your usual peri fatigue - you know the difference)
- Nausea or vomiting
- Unusual itching
- Light-colored stools
- Yellowing of your eyes or skin (jaundice)
- Dark urine
- Swelling in your belly area
- Pain in the right upper abdomen
Keep this list with the pill bottle. That's not fear-mongering; that's the drug's own instructions, in the FDA's own words. Every serious drug with a real risk has a version of this. This one is just unusually well-written.
Veozah vs Lynkuet: the honest comparison
| | Veozah (fezolinetant) | Lynkuet (elinzanetant) | |---|---|---| | Approved | May 2023 | Oct 24, 2025 | | What it does | Blocks neurokinin signaling in the temperature pathway | Same class; per NYT reporting, blocks two neurokinin receptors where Veozah blocks one | | Dose | Pill, once daily | Two 60 mg capsules at bedtime (one with certain meds) | | Evidence base | FDA approval + postmarketing safety data | OASIS-1/2/3 trials, 1,423 participants Established: FDA | | US availability | Available | Expected from November 2026 per reporting Reported: NYT | | The catch | Boxed warning + monitoring schedule | Newer; less real-world data; availability lag |
The practical takeaway: Lynkuet is the newer sibling with the shiny approval and the one-week-improvement headlines, but Veozah has the real-world track record - including the safety event that produced the monitoring schedule. "Newer" is not automatically "safer" or "better." Both are prescription drugs that require a clinician conversation. That conversation, not the pill, is the decision.
What the evidence actually supports
Let's be precise about what is and isn't established:
- Established: Both drugs are FDA-approved for moderate to severe hot flashes from menopause Established: FDA Established: FDA.
- Established: Veozah carries a boxed warning for rare but serious liver injury, with a specific monitoring schedule and stop-on-symptom list Established: FDA.
- Reported, not yet established: Lynkuet's two-receptor mechanism and one-week improvement framing come from press coverage of the approval, not from a head-to-head trial against Veozah Reported: NYT.
- Not established: that either pill is "better" than the other, or that either beats hormone therapy for women who can take hormones. HRT remains the evidence-backed first-line option for eligible women with bothersome symptoms Established: Mayo Clinic.
The honest alternatives section
For women who can't or won't take hormones, the non-hormonal pill lane is real - but it is not the only lane:
- Nonhormonal prescriptions. Fezolinetant and elinzanetant are the new kids; there are also nonhormonal options in other classes that have been around longer Established: OWH.
- The practical stuff that is still real. Layers you can shed mid-meeting, a fan that lives in your bag, a bedroom kept genuinely cool, knowing your triggers. None of it cures a hot flash; all of it makes the nights and the meetings better Established: OWH Established: Mayo Clinic.
- The clinician conversation. The Menopause Society keeps a directory of menopause-competent clinicians at menopause.org Established: Menopause Society. This is a prescription decision - bring your history, your med list, and your symptoms, and let someone who knows the territory map the options.
The bottom line
You are not being dramatic for noticing that "new miracle pill" and "boxed warning" are in the same sentence. That tension is real, and it's also the point: this is a drug class with a genuine safety system built around a genuine risk, which is exactly what you want from a medicine that exists because the alternative was nothing.
The searches "veozah liver damage" and "is veozah safe" deserve the same answer: the risk is rare, it is monitored on a named schedule (before, monthly x3, months 6 and 9), and there is a specific list of symptoms that means stop and call. Bring the schedule and the list to your clinician, ask the questions at the bottom of this article, and let the evidence - not the headlines - make the call. The pill is the easy part. The conversation is the treatment.
